The long-term usage of non-steroidal anti-inflammatories (NSAIDs) has always concerned me. Through the years I have taken different types of NSAIDs for varying periods. These NSAIDs even included (for a short time) VIOXX, which was pulled off the shelves in 2004 after studies confirmed that it increased the risk of heart attack and stroke. For many years I have taken diclofenac, which now researchers also believe carries a high cardiovascular risk, especially for people with a history of heart disease or other risk factors such as diabetes or high cholesterol. Continue reading
Do you have psoriatic arthritis or care for someone who does? We need your valuable input.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for certolizumab pegol (Cimzia®) for the treatment of psoriatic arthritis (PsA). Certolizumab pegol is indicated for use in combination with methotrexate for reducing signs and symptoms and inhibiting the progression of structural damage as assessed by X-ray, in adult patients with moderately to severely active psoriatic arthritis who have failed one or more disease-modifying anti-rheumatic drugs (DMARDs). Continue reading
“One needle, only one time.” This statement may seem obvious in the context of any medical practice but as guest author on the Centers for Disease Control blog Dr. John O’Keefe notes in his article, Moving the Needle to Safe Dentistry, that rule, alarmingly, is not always followed.
As a result, the “One & Only Campaign” was created to raise awareness among patients and healthcare providers about safe injection practices. Led by the Centers for Disease Control and Prevention (CDC) and the Safe Injection Practices Coalition (SIPC), the campaign aims to eradicate outbreaks resulting from unsafe injection practices.
Dr. O’Keefe is a dentist and board chairman for the Organization for Safety, Asepsis and Prevention (OSAP), which is the dental sector’s premier organization dedicated to infection prevention and control. OSAP, disappointed when it discovered that unsafe practices in a U.S. dental setting led to the first documented patient-to-patient case of hepatitis C last year, has joined forces with the CDC and SIPC. Click here to read the full article.
A recent research from the University of Southampton shows that the arthritis medication, etanarcept (Enbrel®), may slow Alzheimer’s disease. The research was presented at the Alzheimer’s Association International Conference in Denmark last week.
In the small control study, a group of 41 patients exhibiting mild or moderate Alzheimer’s was given either the anti-inflammatory medication etanercept or a placebo every week over a period of six months.
Researchers monitored memory function in patients and found that the efficiency of day-to-day activities and behaviour and the symptoms of those who had taken etanercept did not get any worse. In comparison, the placebo group showed signs of decline in memory function.
In an interview with the Daily Mail, lead researcher, Professor Clive Holmes, said:
Last week, my computer mouse inadvertently hovered over some advertising scrolling along the screen and I was instantly transported to another website.
This is not the first time this has happened, but before I became involved in an investment pitch or a cure for belly fat (both of which I probably could use), I warned myself to be remain vigilant and then repeatedly hit the “back” button until I was safely back on the terra firma of my home page. Continue reading
Innovation in Action: Annual arthritis conference brings experts from around the globe to share research, improve patient care
The American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals (ARHP) meet once a year, bringing researchers from around the world together so they may share information and discuss the latest science, research, and treatments in the field of rheumatology. Innovative sessions, groundbreaking science, education that fills knowledge and practice gaps, and hands-on skills training make up some of the activities of the event.
The goals of the annual conference include:
- Identifying developments in disease diagnosis and treatments.
- Describing potential issues in delivery of care and sharing ideas for solutions.
- Summarizing recent research findings.
- Using new research data to improve the quality of patient care.
- Encouraging research that leads to new treatment protocols.
Arthritis Consumer Experts was at the most recent event, held in October 2013, to represent people living with arthritis and to learn about the latest research findings so we could share them with you. Of particular interest to consumers were two presentations: One was about the current state of osteoarthritis treatment and ways to improve outcomes in the future. The other discussed recent advances in psoriatic arthritis research and how they could be used to effectively identify, diagnose, and treat the disease to improve patients’ quality of life and function. Continue reading